The Phase 3 study for Sarclisa® (isatuximab) delays disease progression in newly diagnosed multiple myeloma patients who are unsuitable for stem cell transplantation.

Wave Life Sciences has launched the first stage of treatment in its RestorAATion study, which assesses the pioneering RNA editing treatment, WVE-006, aimed at combatting Alpha-1 Antitrypsin Deficiency.

CatalYm Reports Promising Results for Phase 2a Trial with Visugromab Treating Late-Stage NSCLC and Bladder Cancer During the 2023 ESMO Immuno-Oncology Meeting.

Bolt Biotherapeutics Commences Phase 2 Clinical Trial Enrollment for BDC-1001 in HER2-Positive Breast Cancer Subjects Previously Administered Enhertu.

Coherus Showcases Early-Stage Study Results for its Novel IL-27-Specific Antibody, Casdozokitug, at ESMO's 2023 Immuno-Oncology Meeting.

Qilu Pharma Reports Data on Phase 2 Trial of Iparomlimab in Treating Progressive Solid Cancers, Reveals 45.8% Objective Response Rate at ESMO Asia Conference.

First patient with swiftly advancing ANCA-Related Vasculitis and kidney inflammation enrolled and treated in Phase II study of new drug Lixudebart (ALE.F02) by Alentis Therapeutics.

GT Biopharma, Inc., a clinical-stage immuno-oncology company, is committed to developing innovative therapies using its proprietary TriKE® NK cell technology. The firm recently announced it filed an IND application with the US FDA for its new drug, GTB-3650.

Everest Medicines, a biopharma company, announced that China's National Medical Products Administration has accepted their IND application for the drug candidate zetomipzomib in China.

FDA Grants Approval for CARsgen's Experimental Treatment CT071 for Use in Cases of Recurrent Multiple Myeloma and Primary Plasma Cell Leukemia After Prior Therapies Fail.

Brenig Therapeutics Reveals Enhanced Safety Metrics for its LRRK2 Blocker BT-0267 Featuring Notable CSF-to-Blood Concentration at the Parkinson's Disease Symposium.

The prominent science and technology corporation, Merck, has declared a formal licensing contract with the Shanghai-based firm Abbisko Therapeutics Co. Ltd.